The North America Lymphoma Therapeutics Market should witness market growth of 7.3% CAGR during the forecast period (2023-2029).
The primary element that is projected to be the primary driver of growth in the lymphoma treatment market is an increase in research and development activities among key companies for the development of lymphoma therapies with fewer side effects. This is the primary driver anticipated to foster growth in the lymphoma treatment market. On the other hand, new possibilities will likely arise during the projected period due to the public's growing awareness of lymphoma and the various treatment choices available for the disease.
On the other hand, it is anticipated that the increasing incidence of non-Hodgkin lymphoma, as well as the rise in awareness and concern over the accessibility of a variety of treatment choices for lymphoma, would present lucrative chances for the expansion of the lymphoma therapeutics market throughout the course of the forecast period.
An unprecedented rise in the market for lymphoma therapeutics is anticipated to be driven by substantial unmet clinical needs connected to the illness as well as the launch of new products. In addition, the prospective drug pipeline, shifting treatment trends, increasing prevalence of lymphoma, higher finance from several countries, increased awareness, and faster approvals supplied by regulatory bodies are all factors driving the revenue growth of the market.
In the United States, investments have reduced the incidence of new cancer cases and cancer-related fatalities over the past few decades. Aligned with this trend, the overall count of cancer survivors within the United States has increased from 7 million in 1992 to surpassing fifteen million in 2016, with an estimated surge to exceed 26 million by 2040. In addition, as a result of advancements in cancer detection, diagnosis, and patient care, people are leading longer and healthier lives than ever before. Hence, the constant effort by the government to decrease the deaths from various types of cancer like lymphoma and create effective therapeutics measures is expected to increase the development and utilization of lymphoma therapeutics and therefore aid the market to grow in the region.
The US market dominated the North America Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $6,819.7 million by 2029. The Canada market is poised to grow at a CAGR of 9.7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 8.7% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
The primary element that is projected to be the primary driver of growth in the lymphoma treatment market is an increase in research and development activities among key companies for the development of lymphoma therapies with fewer side effects. This is the primary driver anticipated to foster growth in the lymphoma treatment market. On the other hand, new possibilities will likely arise during the projected period due to the public's growing awareness of lymphoma and the various treatment choices available for the disease.
On the other hand, it is anticipated that the increasing incidence of non-Hodgkin lymphoma, as well as the rise in awareness and concern over the accessibility of a variety of treatment choices for lymphoma, would present lucrative chances for the expansion of the lymphoma therapeutics market throughout the course of the forecast period.
An unprecedented rise in the market for lymphoma therapeutics is anticipated to be driven by substantial unmet clinical needs connected to the illness as well as the launch of new products. In addition, the prospective drug pipeline, shifting treatment trends, increasing prevalence of lymphoma, higher finance from several countries, increased awareness, and faster approvals supplied by regulatory bodies are all factors driving the revenue growth of the market.
In the United States, investments have reduced the incidence of new cancer cases and cancer-related fatalities over the past few decades. Aligned with this trend, the overall count of cancer survivors within the United States has increased from 7 million in 1992 to surpassing fifteen million in 2016, with an estimated surge to exceed 26 million by 2040. In addition, as a result of advancements in cancer detection, diagnosis, and patient care, people are leading longer and healthier lives than ever before. Hence, the constant effort by the government to decrease the deaths from various types of cancer like lymphoma and create effective therapeutics measures is expected to increase the development and utilization of lymphoma therapeutics and therefore aid the market to grow in the region.
The US market dominated the North America Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $6,819.7 million by 2029. The Canada market is poised to grow at a CAGR of 9.7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 8.7% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
- Injectable
- Oral Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Lymphoma Therapeutics Market, by Treatment Type
1.4.2 North America Lymphoma Therapeutics Market, by Disease Type
1.4.3 North America Lymphoma Therapeutics Market, by Route of Administration
1.4.4 North America Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 North America Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Lymphoma Therapeutics Market by Treatment Type
4.1 North America Immune Therapy Market by Country
4.2 North America Target Therapy Market by Country
4.3 North America Chemotherapy Market by Country
4.4 North America Radiation Therapy Market by Country
Chapter 5. North America Lymphoma Therapeutics Market by Disease Type
5.1 North America Non-Hodgkin Lymphoma Market by Country
5.2 North America Hodgkin Lymphoma Market by Country
Chapter 6. North America Lymphoma Therapeutics Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Route Market by Country
Chapter 7. North America Lymphoma Therapeutics Market by Distribution Channel
7.1 North America Hospital Pharmacies Market by Country
7.2 North America Retail Pharmacies Market by Country
7.3 North America Others Market by Country
Chapter 8. North America Lymphoma Therapeutics Market by Country
8.1 US Lymphoma Therapeutics Market
8.1.1 US Lymphoma Therapeutics Market by Treatment Type
8.1.2 US Lymphoma Therapeutics Market by Disease Type
8.1.3 US Lymphoma Therapeutics Market by Route of Administration
8.1.4 US Lymphoma Therapeutics Market by Distribution Channel
8.2 Canada Lymphoma Therapeutics Market
8.2.1 Canada Lymphoma Therapeutics Market by Treatment Type
8.2.2 Canada Lymphoma Therapeutics Market by Disease Type
8.2.3 Canada Lymphoma Therapeutics Market by Route of Administration
8.2.4 Canada Lymphoma Therapeutics Market by Distribution Channel
8.3 Mexico Lymphoma Therapeutics Market
8.3.1 Mexico Lymphoma Therapeutics Market by Treatment Type
8.3.2 Mexico Lymphoma Therapeutics Market by Disease Type
8.3.3 Mexico Lymphoma Therapeutics Market by Route of Administration
8.3.4 Mexico Lymphoma Therapeutics Market by Distribution Channel
8.4 Rest of North America Lymphoma Therapeutics Market
8.4.1 Rest of North America Lymphoma Therapeutics Market by Treatment Type
8.4.2 Rest of North America Lymphoma Therapeutics Market by Disease Type
8.4.3 Rest of North America Lymphoma Therapeutics Market by Route of Administration
8.4.4 Rest of North America Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Methodology
LOADING...
